Dr. Fiona Ginty, another GE senior scientist and the study's senior author, added: "The more cell-level data we analyze, the more we learn about tumor biology, cell-to-cell interactions, immune response and how tumors progress. Further, with the integration of cellular, medical imaging and genomic data, we gain a more holistic understanding of why certain tumor types progress more rapidly, and others are more slow-growing, and ultimately which drugs a patient may respond to."

Researchers' next step will be to use this new technology on a large cohort of patients to prove that it works.


Also contributing to this study were: Case Western Reserve University School of Medicine, Prairie View A&M University, Seidman Cancer Center, and the University of California San Francisco.

This study -- Multiscale, multimodal analysis of tumor heterogeneity in IDA1 mutant vs wild-type diffuse gliomas -- was funded by the National Institutes of Health, General Electric Global Research, and The Ben & Catherine Ivy Foundation. Additional funding was provided by: Case Comprehensive Cancer Center, the Sally S. Morley Designated Professorship in Brain Tumor Research, the Peter Cristal Endowed Professorship in Neurooncological Surgery, Texas A&M University, Prairie View A&M University, the Center for Excellence for Translational Neuro-Oncology, the Kimble Family Foundation, the Gerald Kaufman Fund for Glioma Research, and the Ferry Family Foundation at University Hospitals of Cleveland.


About TGen, an affiliate of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: http://www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process.

Back to HCB News

MRI Homepage